Chih Hui Lin

Chief Executive Officer presso SYNMOSA BIOPHARMA CORPORATION

Health Technology

Consumer Services

Profilo

Chih Hui Lin is currently the Chairman, President & General Manager at Synmosa Biopharma Corp.
He is also the Chairman at Yu Chiao Co. Ltd., InnoPharmax, Inc., U-Liang Pharmaceutical Co. Ltd., and Intech Biopharm Ltd.
Mr. Lin completed his undergraduate degree at Taipei Medical University.

Posizioni attive di Chih Hui Lin

Società	Posizione	Inizio
SYNMOSA BIOPHARMA CORPORATION	Chief Executive Officer	25/02/2011
INNOPHARMAX INC.	Chairman	21/03/2008
INTECH BIOPHARM CORPORATION	Chairman	28/10/2010
Yu Chiao Co. Ltd.	Chairman	-
U-Liang Pharmaceutical Co. Ltd. U-Liang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Synmosa Biopharma Corp., U-Liang Pharmaceutical Co. Ltd. is a Taiwanese company that manufactures and distributes pharmaceutical products. The private company is based in Taoyuan, Taiwan. U-Liang Pharmaceutical Co. was acquired by Synmosa Biopharma Corp. on March 07, 2013 for $2.50 million.	Chairman	-

Tutte le posizioni attive di Chih Hui Lin

Formazione di Chih Hui Lin

Taipei Medical University

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Chih Hui Lin

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	3
SYNMOSA BIOPHARMA CORPORATION	Health Technology
INNOPHARMAX INC.	Health Technology
INTECH BIOPHARM CORPORATION	Health Technology

Aziende private	2
Yu Chiao Co. Ltd.
U-Liang Pharmaceutical Co. Ltd. U-Liang Pharmaceutical Co. Ltd. Pharmaceuticals: MajorHealth Technology Part of Synmosa Biopharma Corp., U-Liang Pharmaceutical Co. Ltd. is a Taiwanese company that manufactures and distributes pharmaceutical products. The private company is based in Taoyuan, Taiwan. U-Liang Pharmaceutical Co. was acquired by Synmosa Biopharma Corp. on March 07, 2013 for $2.50 million.	Health Technology